Cyxone Initiates Feasibility Preclinical Studies to Optimize Path Forward for Multiple Sclerosis Drug Candidate T20K
Cyxone announced today the initiation of key preclinical studies required to enable taking Multiple Sclerosis drug candidate T20K forward. Firstly, the company will select a Contract Manufacturing Organization (CMO) to establish a new manufacturing process to produce larger quantities of GMP (Good Manufacturing Practice) grade material needed in further preclinical and clinical studies.
Furthermore, while Cyxone continues to develop the oral administration form for T20K, the company has also decided to initiate a feasibility study on a subcutaneous administration form in Q2 2021. Finally, biomarker development to support both administration forms will be completed.
“We have spent the past year exploring different options for the manufacture of T20K and are now in the position to select a partner and initiate this critical step. The outcome of this study aims to provide Cyxone with an outline for a robust, scalable manufacturing process for the drug substance in more than sufficient amounts as required to further progress the T20K program,” says Tara Heitner, CEO. “The initiation of studies in alternative administration forms and biomarker development for T20K will also serve to de-risk drug development and help support transition to clinical studies. I am very pleased with the progress the company has made in the past year.”
Contact
Tara Heitner, CEO
Tel: +46 70 781 88 08
Email: tara.heitner@cyxone.com
Adelgatan 21
211 22 Malmö, Sweden
About Cyxone
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, ca@mangold.se. For more information, please visit www.cyxone.com
Tags: